Shilpa Medicare Limited
  

Shilpa Medicare Limited has carved a niche for itself in the exceedingly competitive and ... More>>

 

Our EOU unit certified by ISO 14001:2004

Our R&D Centre is approved by DSIR, Govt of India on 19.01.2011

Our facility is audited and approved by PMDA-Japan on 25.01.2011

COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00 )

Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl COS received from EDQM for Carboplatin (R0-CEP 2006-212-Rev.00)

COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)

COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)

Ambroxol MF Holder & Site Registered with PMDA, Japan

Site inspected Effectively by TGA, Australia

Export Excellence Award-2010 received from FKCCI & VITC, Bangalore

Obtained EUGMP Certificate for Gemcitabine HCl EP from AFSSAPS, France

Obtained EUGMP Certificate for Temozolomide (Unit-1) & Capecitabine (Unit-2) from BSG, Hamburg

Obtained EUGMP Certificate for Anastrozole, Irinotecan & Oxaliplatin from INFARMED, Portugal

Filed USDMF of Anastrozole, Temozolomide, Irinotecan, Oxaliplatin with USFDA

Patent Filed for Novel Polymorphic Form of Bortezomib (160/CHE/2010)

 
 
  
The QA Department ensures that the manufacturing... More>>
 
 
  
Shilpa Medicare is a fast growing pharma... More>>
 
  
Click here>>
 
State-of-the-art facilities at Shilpa are geared to manufacture... More>>
EUGMP from Afssaps, Infarmed, BSG & GMP from TGA & Health ... More>>
 
 
Copyrights Reserved 2007. Shilpa Medicare Ltd. Disclaimer
Maintained by : vdesign2shine
 
 
 
 
Shilpa Medicare Limited